CDK12 and cancer: Namely, we conducted GSEA of gene expression changes from multiple CDK12-inhibited cancer cell lines, including THZ531-treated melanoma A-375, Colo829 and neuroblastoma IMR-32 cell lines, and triple-negative breast cancer MDA-MB-231 cell line treated with CDK12 inhibitor SR-4835 (10,28,34), which revealed enrichment of the same gene sets (Figure 3B and Supplementary Table S2B-E).